We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current NSB market cap is 6.51M. The company's latest EPS is AUD -0.0074 and P/E is -5.41.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 34k | 41k | 1.02M | 0 | 4.95M |
| Operating Income | -1.74M | -2.9M | -3.21M | -10.5M | -1.17M |
| Net Income | -1.66M | -2.87M | -3.18M | -10.44M | -1.07M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 5.12M | 3.74M | 14.83M | 7.74M | 5.29M |
| Total Liabilities | 62k | 89k | 223k | 2.22M | 597k |
| Total Equity | 5.06M | 3.65M | 14.6M | 5.52M | 4.69M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -1.41M | -2.28M | -2.6M | -6.94M | -2.3M |
| Investing | -19k | -2k | -30k | -4k | N/A |
| Financing | 5.93M | 961k | 13.51M | N/A | N/A |
| Market Cap | 6.51M |
| Price to Earnings Ratio | -5.41 |
| Price to Sales Ratio | 1.17 |
| Price to Cash Ratio | 1.18 |
| Price to Book Ratio | 1.23 |
| Dividend Yield | - |
| Shares Outstanding | 144.6M |
| Average Volume (1 week) | 127.62k |
| Average Volume (1 Month) | 156.94k |
| 52 Week Change | -57.14% |
| 52 Week High | 0.14 |
| 52 Week Low | 0.035 |
| Spread (Intraday) | 0 (4.26%) |
| Company Name | Neuroscientific Biopharmaceuticals Ltd |
| Address |
suite 5 perth, western australia 6011 |
| Website | https://www.neuroscientific.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
